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Background and Purpose  Associations between alterations in body mass index (BMI) and 
cognitive function have been reported in Parkinson’s disease (PD). We investigated whether 
the BMI at a PD diagnosis is associated with cognitive decline and the future development of 
dementia.
Methods  We recruited 70 patients with de novo PD who underwent neuropsychological 
testing every 3 years and were followed up for more than 6 years. We classified patients into 
the following three groups based on their BMI at the diagnosis: under-/normal weight (n=21), 
overweight (n=22), and obese (n=27). We evaluated differences in the rate of cognitive decline 
over time among the groups using linear mixed models and the conversion rate to dementia 
using survival analysis.
Results  The obese patients with PD showed a slower deterioration of global cognitive func-
tion as well as language and memory functions than did the under-/normal-weight group 
during the 6-year follow-up. The three BMI groups showed different rates of conversion to de-
mentia (log-rank test: p=0.026). The combined overweight and obese group showed a lower 
risk of developing dementia compared with the under-/normal-weight group (hazard ratio= 
0.36, 95% CI=0.12–0.82, p=0.046).
Conclusions  We have demonstrated that a higher-than-normal BMI at the time of a PD diag-
nosis has a protective effect against the deterioration of cognitive function and the conversion to 
dementia.
Key Words   body mass index, cognitive decline, neuropsychological test, Parkinson disease, 
Parkinson’s disease dementia.
The Influence of Body Mass Index at Diagnosis 
on Cognitive Decline in Parkinson’s Disease
INTRODUCTION
Alterations in body mass index (BMI) and body weight are known to be associated with 
Parkinson’s disease (PD) and its various motor and nonmotor symptoms.1,2 However, a 
clear correlation between BMI and PD has not yet been established. Patients with PD were 
found to have a lower BMI than controls in a meta-analysis,1 while overweight and normal-
weight individuals were more prevalent in the PD group in another cross-sectional study.3 
There have also been conflicting reports on whether patients with PD gain or lose weight be-
tween before and after their diagnosis. One prospective study found that patients with PD 
lost weight compared with several years before the diagnosis,4 while a case–control study 
found no changes in BMI after the onset of PD,5 and a community-based study observed 
weight gain during early PD.6 
The association between BMI and cognitive function has been investigated in numerous 
healthy and diseased populations. In cognitively normal populations, the association be-
tween BMI and cognitive function varies with age. A higher BMI in midlife is associated 
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with a higher risk of dementia, whereas the association is re-
versed in late life.7 In patients with mild cognitive impairment 
(MCI) or Alzheimer’s disease (AD), a lower BMI is associated 
with faster cognitive decline and a higher risk of developing 
dementia.8,9 PD patients whose BMI or weight decreased dur-
ing follow-up showed a worse baseline cognition or a faster 
cognitive decline than those who maintained a stable BMI or 
weight.10-12 However, no studies have examined in detail the 
pattern of deterioration in each cognitive domain according to 
BMI in patients with PD.
Therefore, the aim of this study was to determine wheth-
er the BMI at the diagnosis in patients with de novo PD in-
fluences the subsequent cognitive decline and the future de-
velopment of dementia. We also investigated the pattern of 
cognitive dysfunction in terms of the overall cognitive ability 
and the ability in each cognitive domain over 6 years of fol-
low-up.
METHODS
Study design and patients
This retrospective cohort study enrolled patients with PD 
from the Movement Disorders outpatient clinic in the Yonsei 
University Severance Hospital. We enrolled 123 drug-naïve 
patients in the PD cognition cohort who between June 2008 
and August 2012 had completed baseline evaluations in-
cluding neuropsychological tests (NPs), brain MRI, and N-[3-
(18F)fluoropropyl]- 2β-carbon ethoxy-3β-(4-iodophenyl) 
nortropane (18F-FP-CIT) PET. The patients were followed up 
longitudinally while they underwent NPs every 3 years. At 
the baseline evaluation, we excluded patients with PD who 
were illiterate, already met the criteria for dementia, had severe 
white-matter hyperintensities (WMHs),13 or had developed 
PD when younger than 40 years (n=3). During the longitu-
dinal follow-up we further excluded patients from among 
the 102 eligible patients who had follow-up durations shorter 
than 6 years, were diagnosed with disorders other than PD, 
or had neurological or psychiatric illnesses or medical co-
morbidities that affect cognition. We finally enrolled 70 pa-
tients with PD who had been followed up for more than 6 
years and underwent regular NPs every 3 years. The enroll-
ment flowchart for the study patients is presented in Fig. 1.
PD was diagnosed based on the clinical diagnostic crite-
ria of the United Kingdom PD Society Brain Bank.14 All pa-
tients showed excellent responses to dopaminergic medica-
tion and had decreased dopamine transporter availability on 
18F-FP-CIT scans. The Institutional Review Board of Yonsei 
University Severance Hospital approved this study (IRB No. 
4-2016-0210). Written informed consent was obtained from 
all subjects who participated in this study.
Clinical assessment
The baseline height and weight were measured in all patients 
at their initial visits, from which the BMI was calculated. Ac-
cording to the revised Asia-Pacific BMI criteria of the World 
Health Organization for western Pacific regions, BMI was clas-
sified as follows based on Asians tending to have larger 
amounts of abdominal fat at lower BMIs15: underweight, BMI< 
18.5 kg/m2; normal weight, BMI ≥18.5 and <23 kg/m2; over-
weight, BMI ≥23 kg/m2 and <25 kg/m2; and obese, BMI ≥25 
PD cognition cohort 
from June 2008 to August 2012 (n=123): 
Baseline evaluation
Excluded (n=21) 
   • PD patients with illiteracy (n=7) 
   • Dementia at baseline (n=6) 
   • Severe white matter hyperintensities (n=5)
   • Onset age less than 40 years old (n=3)
Excluded (n=32) 
   • Follow-up duration less than 6 years (n=18) 
   • Diagnosis other than PD (n=6) 
   • Neurologic, psychiatric, or metabolic illnesses (n=8)
Eligible subjects (n=102): 
Longitudinal follow-up
Enrolled subjects (n=70)
Under/normal weight 
group (n=21)
Overweight group 
(n=22)
Obese group 
(n=27)
Fig. 1. Flowchart of the study patients with PD. PD: Parkinson’s disease.
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kg/m2. We divided the patients with PD into the following 
three groups: under-/normal weight, BMI <23 kg/m2 (n=21); 
overweight, BMI ≥23 and <25 kg/m2 (n=22), and obese, 
BMI ≥25 kg/m2 (n=27). The underweight participants were 
pooled with the normal-weight group because there were 
only three patients who had a BMI below 18.5 kg/m2.
We evaluated parkinsonian motor symptoms during a 
drug-naïve state at the time of 18F-FP-CIT PET scan acqui-
sition using the Unified Parkinson’s Disease Rating Scale (UP-
DRS) activities of daily living (UPDRS-II) and motor (UPDRS-
III) subscales. We classified patients with PD according to 
clinical phenotypes into tremor-dominant or postural-insta-
bility/gait-difficulty parkinsonism.16 Other clinical indicators 
that could affect cognitive function were also measured, in-
cluding the Beck Depression Inventory (BDI) for depression17 
and the Cross-Cultural Smell Identification Test (CCSIT) for 
olfactory function.18 The levodopa-equivalent dose (LED) 
was calculated according to a previously described method.19
MRI scan acquisition and parameters
All MRI scans were acquired using a Philips 3-T scanner 
(Philips Intera, Philips Medical System, Best, the Netherlands) 
with a SENSE head coil (SENSE factor=2). Based on MRI 
images, we assessed visual rating scales of medial temporal at-
rophy (MTA) using Scheltens’ scale (grade 0–4)20 and WMHs 
using the Fazekas scale (score 0–3 for periventricular and deep 
WMHs).13 The method used for MRI scan acquisition and the 
MRI parameters are described in detail in the Supplementary 
Material (in the online-only Data Supplement).
Neuropsychological evaluation and assessment of 
cognitive function
All patients underwent a standardized and comprehensive 
neuropsychological battery, the Seoul Neuropsychological 
Screening Battery,21 which covers five cognitive domains: 1) 
digit-span task and Stroop test for the attention domain, 2) 
the Korean version of the Boston Naming Test for the lan-
guage domain, 3) the Rey-Osterrieth Complex-Figure Test 
(RCFT) copying and pentagon-drawing test for the visuospa-
tial domain, 4) the Seoul Verbal Learning Test and RCFT 
(both immediate recall, 20-min delayed recall, and recogni-
tion) for the memory domain, and 5) the clock-drawing test 
and the Controlled Oral Word-Association Test for the fron-
tal executive domain. Standardized z-scores are available 
for all scorable tests based on age- and education-matched 
norms. We considered a score for each cognitive item as ab-
normal when it was more than 1.5 SDs lower than the mean. 
Composite scores of each cognitive domain were calculated 
by dividing the sum of the z-scores by the number of tests. 
We calculated the following three summary scores to assess 
global cognitive performance: global z-score composite de-
rived by averaging all z-scores, total Mini Mental State Ex-
amination (MMSE) score, and Clinical Dementia Rating 
Sum of Boxes (CDR-SOB).
PD with intact cognition was considered to be present when 
a subject had impairment on fewer than two items of the NP. 
PD with MCI was diagnosed based on level II criteria in ac-
cordance with the Movement Disorder Society Task Force 
guideline.22 PD patients with MCI reported subjective cogni-
tive complaints and showed no evidence for abnormality when 
performing the activities of daily living, as judged both clini-
cally and based on the Instrumental Activities of Daily Liv-
ing scale. Patients were diagnosed with Parkinson’s disease 
dementia (PDD) if they fulfilled its clinical criteria.23
Statistical analyses
Differences in demographics and NP results among the BMI 
groups were determined using nonparametric analysis. The 
Kruskal-Wallis test was used for continuous variables, and the 
obtained data were expressed as mean±SD values, while Pear-
son’s χ2 test was applied to categorical variables, and the ob-
tained data were expressed as a numbers and percentages. We 
used a linear mixed model with random and fixed effects to 
evaluate differences in the cognitive decline rate according to 
the BMI groups while adjusting for the age at PD onset, sex, 
years of education, UPDRS motor scores, and clinical pheno-
type. Post-hoc between-group and between-time comparisons 
were performed when the cognitive performance was found 
to differ after applying repeated measures. We performed a 
Kaplan-Meier analysis of the probability of progression to 
PDD and used a log-rank test to compare the Kaplan-Meier 
plots of the groups. Post-hoc subgroup analyses were per-
formed using Bonferroni correction. The hazard ratio (HR) 
for converting to PDD was calculated using a Cox propor-
tional-hazards model with covariates of age at PD onset, sex, 
years of education, and UPDRS motor score.
RESULTS
Baseline clinical and imaging characteristics
The clinical and imaging characteristics of the patients with 
PD are summarized in Table 1. All clinical variables includ-
ing age, sex, years of education, disease and follow-up dura-
tions, UPDRS motor score, CCSIT score, BDI score, LED at 
the last NP, number of vascular risk factors, MTA grade, and 
WMHs score did not differ across the BMI groups.
Neuropsychological profiles
Table 2 presents the neuropsychological profiles of the pa-
tients with PD. There were no differences between the BMI 
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groups in the distributions for the cognitive status and amnes-
tic components at the initial neuropsychological evaluation, 
while there were differences in those for the cognitive status 
at the last NP. The proportion of those who converted to de-
mentia during the follow-up period was higher in the under-/
normal-weight group than in the overweight and obese groups, 
while all BMI groups contained comparable proportions of 
those who converted to MCI. There were no significant dif-
ferences in age at the initial NP, the duration from PD onset 
to the baseline NP, or in the performance in each cognitive 
domain and global cognitive function at baseline. The dura-
tion from PD onset to PDD conversion did not differ among 
the PDD converters in the groups.
Comparison of the progression of cognitive decline
The longitudinal changes in cognitive function were com-
pared in patients with PD grouped according to BMI (Table 
3 and Fig. 2). A linear mixed model showed that the rates of 
decline in language, memory, total MMSE scores, and CDR-
SOB differed between the BMI groups. After post-hoc anal-
ysis of the between-group comparison, the overweight and 
obese groups performed better in language function at the 3- 
year follow-up compared to the under-/normal-weight group. 
The language function at the 6-year follow-up was better in 
the obese group than the under-/normal-weight group. The 
overweight and obese groups showed a better cognitive per-
formance in memory tasks at the 6-year follow-up com-
pared to the under-/normal-weight group. The obese group 
showed a slower progression in CDR-SOB compared to the 
under-/normal-weight group at the 6-year follow-up. There 
were no differences between the overweight and obese groups 
in cognitive function at the 3-year and 6-year follow-up NPs. 
The post-hoc analysis of the between-time comparisons 
revealed that the under-/normal-weight group showed signif-
icant deterioration in all cognitive domains and global cog-
nition over 6 years. The overweight group showed significant-
Table 1. Baseline clinical and imaging characteristics of the patients with PD according to BMI
Under-/normal-weight group 
(n=21)
Overweight group 
(n=22)
Obese group 
(n=27)
p
Age at onset, years 66.05±6.79 64.84±6.48 64.94±8.29    0.227
Sex, male 11 (52.4) 10 (45.5) 18 (59.3)    0.628
Education, years 11.02±5.38 10.02±4.95   9.15±5.00    0.441
PD duration, years   8.04±1.89 8.04±1.59   8.07±1.96    0.998
Follow-up duration, years   8.07±1.64 7.97±1.38   7.79±1.56    0.810
BMI, kg/m2 21.22±1.82 23.99±0.72� � 27.21±2.25 <0.001
UPDRS motor score 17.05±9.08 15.73±12.81 18.48±8.63    0.645
Clinical phenotype    0.743
TD parkinsonism   6 (28.6)   8 (36.4) 10 (37.0)
PIGD parkinsonism 10 (47.6) 11 (50.0) 14 (51.9)
Intermediate   5 (23.8)   3 (13.6)   3 (14.3)
BDI score 14.33±8.58 12.27±7.40� � 12.78±6.83    0.649
CCSIT score   6.25±2.69 6.56±1.92   6.04±2.36    0.775
LED at the last NP   769.73±329.24 647.34±160.77   703.27±183.35    0.229
Risk factors
Hypertension   9 (42.9)   7 (31.8) 15 (55.6)    0.247
Diabetes mellitus   3 (14.3)   4 (18.2)   9 (33.3)    0.098
Dyslipidemia   4 (19.0)   5 (22.7)   6 (22.2)    0.950
Ischemic heart disease 1 (4.8) 2 (9.1)   5 (18.5)    0.304
Ischemic stroke 2 (9.5) 2 (9.1)   4 (14.8)    0.779
Brain MRI findings
MTA grade, right   1.52±0.51 1.77±0.69   1.48±0.58    0.208
MTA grade, left   1.67±0.48 1.68±0.72   1.44±0.64    0.329
WMHs score, deep   1.19±0.51  1.41±0.73   1.07±0.39    0.112
WMHs score, periventricular   1.19±0.51 1.18±0.50   1.26±0.59    0.859
Data are mean±SD or n (%) values. The Kruskal-Wallis and χ2 tests were used for comparing continuous and categorical variables, respectively.
BDI: Beck Depression Inventory, BMI: body mass index, CCSIT: Cross-Cultural Smell Identification Test, LED: levodopa-equivalent dose, MTA: medial 
temporal atrophy, NP: neuropsychological test, PD: Parkinson’s disease, PIGD: postural instability/gait difficulty, TD: tremor dominant, UPDRS: Unified 
Parkinson’s Disease Rating Scale, WMHs: white-matter hyperintensities.
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ly worse cognitive performance in frontal executive function, 
lower MMSE score, and higher CDR-SOB at the 6-year fol-
low-up compared to baseline. The obese group experienced 
a significant decline in visuospatial function at the 3-year 
follow-up compared to baseline, in frontal executive func-
tion at the 6-year follow-up compared to baseline, and in total 
MMSE score at the 6-year follow-up compared to both base-
line and the 3-year follow-up.
BMI as a predictor of conversion to PDD
Kaplan-Meier analyses were applied to the time to PDD con-
version among the overall patients with PD and within the 
three BMI groups (Fig. 3). The conversion rate to dementia in 
de novo patients with PD was 31.4% (n=22) during 6 years 
of follow-up, which is similar to the rate found in a previous 
20-year longitudinal study (Fig. 3A).24 The BMI groups showed 
different conversion rates to dementia (by log-rank test, p= 
0.026) (Fig. 3A). After a post-hoc between-group comparison, 
the overweight group (by log-rank test, p=0.001) and the 
obese group (by log-rank test, p=0.002) had significantly low-
er rates of conversion to dementia than the under-/normal-
weight group. When combining the overweight and obese 
groups, PD patients with BMI ≥23 kg/m2 had a lower con-
version rate to dementia than did those with BMI <23 kg/m2 
(by log-rank test, p=0.007) (Fig. 3B). After adjusting for the 
age at PD onset, sex, years of education, and UPDRS motor 
score, the HR of the combined overweight and obese groups 
was 0.36 (95% CI=0.12–0.82, p=0.046) compared to the un-
der-/normal-weight group.
DISCUSSION
The present study evaluated whether the degree of cogni-
tive decline is dependent on the BMI at the diagnosis in pa-
tients with de novo PD. Our major findings were as follows: 
1) the baseline demographic and neuropsychological char-
acteristics did not differ across BMI groups in patients with 
PD, except for the proportion of those who converted to de-
mentia being lower in the overweight and obese groups than 
in the under-/normal-weight group; 2) the overweight and 
obese groups showed slower progression of cognitive decline 
in global cognitive function as well as language and memory 
Table 2. Neuropsychological profiles of the PD patients according to BMI
Under-/normal-weight group 
(n=21)
Overweight group 
(n=22)
Obese group 
(n=27)
p
Baseline neuropsychological evaluation
Age at baseline NP, years 67.00±6.86 65.91±6.24 66.00±7.79 0.198
Onset to baseline NP, months   19.52±17.06   18.27±13.66   17.59±19.08 0.925
Cognitive status at initial NP
IC/MCI 10 (47.6)/11 (52.4) 10 (45.5)/12 (54.5) 12 (44.4)/15 (55.6) 0.976
Nonamnestic/amnestic 4 (36.4)/7 (63.6) 6 (50.0)/6 (50.0) 7 (46.7)/8 (53.3) 0.554
Neuropsychological performance (z-score)
Attention composite score   0.06±0.81 -0.09±1.26 -0.04±0.75 0.874
Language composite score  -0.32±0.93   0.06±1.48 -0.13±1.36 0.628
Visuospatial composite score    0.43±1.46 -0.06±2.14   0.27±1.90 0.673
Memory composite score  -0.30±1.02 -0.16±0.98  -0.32±0.88 0.820
Frontal executive composite score  -0.09±1.07 -0.16±1.00  -0.10±1.10 0.679
Global composite score  -0.14±0.73 -0.12±0.96  -0.11±0.73 0.994
Total MMSE score  27.71±2.05 26.77 (2.88) 27.07 (2.63) 0.466
CDR-SOB   1.00±0.71 1.18±1.16   1.24±0.97 0.731
Follow-up neuropsychological evaluation
Cognitive status at last NP
IC/MCI/dementia 3 (14.3)/6 (28.6)/12 (57.1) 8 (36.4)/9 (40.9)/5 (22.7) 11 (40.7)/11 (40.7)/5 (18.5) 0.043†
MCI converters 4/10 (40.0) 3/10 (30.0) 1/12 (8.3) 0.211
PDD converters 12 (57.1) 5 (22.7) 5 (18.5) 0.010*,†
PD onset to PDD, years   4.29±1.12   4.26±1.02 4.41±1.18 0.973
Data are mean±SD or n (%) values. Comparisons of demographic characteristics and each cognitive composite score (z-score) were performed using 
the Kruskal-Wallis and χ2 tests for continuous and categorical variables, respectively. The duration from PD onset to PDD was calculated only in the pa-
tients who have converted to dementia in each BMI group.
Significant differences *Between the under-/normal-weight and overweight groups and †Between the under-/normal-weight and obese groups.
BMI: body mass index, CDR-SOB: Clinical Dementia Rating Sum of Boxes, IC: intact cognition, MCI: mild cognitive impairment, MMSE: Mini Mental 
State Examination, NP: neuropsychological test, PD: Parkinson’s disease, PDD: Parkinson’s disease dementia.
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domains, which are typically involved in AD rather than 
PD;25 and 3) being overweight or obese was associated with 
a significantly lower risk of conversion to PDD compared to 
being underweight or normal weight. These findings indi-
cate that a higher BMI at the diagnosis may serve as a protec-
tive factor against cognitive decline in PD.
The relationship between BMI and cognition in PD has 
rarely been investigated. There are two reports that PD pa-
tients with decreased BMI or weight loss within the first 6 
months to 2 years after the diagnosis showed a faster cogni-
tive decline, based on the MMSE or its modified version be-
ing used to measure cognitive function.10,11 Another study 
made serial measurements of the body weights of patients 
with PD over 6 years, and found that weight loss was associ-
ated with lower scores on the baseline symbol digit modali-
ties test,12 which primarily measures information processing 
speed.26 The present study evaluated the performance in each 
cognitive domain as well as global cognition among subjects 
grouped into BMI tertiles. We found that being overweight or 
obese at the time of PD diagnosis was closely related to slower 
declines in language and memory functions as well as gener-
al cognitive function, and that the difference in cognitive de-
cline became clear over the 6-year follow-up. This indicates 
that a higher-than-normal BMI may play a protective role in 
the progression of cognitive decline in PD.
We evaluated differences in the effects of BMI in each cog-
nitive domain in the presence of PD. Conflicting results have 
been found for the relationship between BMI and each cog-
nitive domain in normal populations. Obesity was associat-
ed with memory, verbal fluency, and visual motor speed,27,28 
but also better performance on attention, reasoning tasks, 
and visuospatial ability.27,29 Such heterogeneous results may 
Table 3. Comparison of longitudinal changes in cognition across time in patients with PD according to BMI
Item
Time, 
years
Group
p 
(group×time)
Post-hoc p
Under-/ 
normal weight
Overweight Obese
Under-/normal 
weight vs. overweight
Under-/normal 
weight vs. obese
Overweight 
vs. obese
Cognitive domain composite
Attention 0 0.05 [0.21] -0.09 [0.20] -0.04 [0.18] 0.366 0.636 0.756 0.850
3 -0.17 [0.20] -0.14 [0.20] -0.12 [0.18] 0.287 0.834 0.356
6 -0.61 [0.24] -0.28 [0.23] -0.55 [0.21] 0.320 0.856 0.382
Language 0 -0.31 [0.28] 0.06 [0.28] -0.14 [0.25] 0.004 0.358 0.645 0.608
3 -1.26 [0.32] -0.13 [0.31] -0.23 [0.28] 0.013 0.018 0.814
6 -1.37 [0.33] -0.71 [0.32] -0.23 [0.29] 0.160 0.012 0.270
Visuospatial 0 0.45 [0.41] -0.07 [0.40] 0.26 [0.36] 0.143 0.364 0.721 0.546
3 -0.24 [0.35] -0.17 [0.34] -0.65 [0.30] 0.881 0.382 0.295
6 -1.64 [0.48] -0.99 [0.47] -0.75 [0.43] 0.338 0.173 0.711
Memory 0 -0.27 [0.21] -0.16 [0.20] -0.26 [0.19] 0.029 0.712 0.829 0.540
3 -0.41 [0.22] -0.16 [0.21] -0.33 [0.18] 0.416 0.610 0.728
6 -1.06 [0.25] -0.32 [0.25] -0.36 [0.22] 0.040 0.041 0.911
Frontal executive 0 -0.09 [0.23] -0.16 [0.23] 0.10 [0.21] 0.736 0.827 0.549 0.401
3 -0.45 [0.21] -0.44 [0.20] -0.15 [0.18] 0.961 0.275 0.291
6 -1.02 [0.22] -0.78 [0.22] -0.49 [0.20] 0.431 0.076 0.328
Global cognition
Global composite 0 -0.13 [0.18] -0.12 [0.17] -0.12 [0.16] 0.053 0.984 0.971 0.998
3 -0.41 [0.19] -0.15 [0.18] -0.23 [0.17] 0.323 0.461 0.760
6 -1.01 [0.23] -0.49 [0.22] -0.45 [0.20] 0.101 0.066 0.897
MMSE 0 27.76 [0.55] 26.61 [0.54] 27.21 [0.49] 0.041 0.231 0.391 0.684
3 26.38 [0.41] 26.70 [0.40] 27.12 [0.36] 0.350 0.258 0.875
6 24.14 [0.72] 25.29 [0.70] 24.98 [0.63] 0.191 0.460 0.518
CDR-SOB 0 1.00 [0.21] 1.18 [0.21] 1.24 [0.19] 0.007 0.414 0.429 0.954
3 1.74 [0.25] 1.27 [0.24] 1.35 [0.22] 0.295 0.250 0.953
6 3.09 [0.43] 2.18 [0.42] 1.56 [0.38] 0.163 0.007 0.191
Data are mean [standard error] values from a linear mixed model after adjusting for age, sex, years of education, and UPDRS motor score. Bonferroni 
corrections were applied for the post-hoc p values.
BMI: body mass index, CDR-SOB: Clinical Dementia Rating Sum of Boxes, MMSE: Mini Mental State Examination, PD: Parkinson’s disease, UPDRS: 
Unified Parkinson’s Disease Rating Scale.
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be attributable to differences between the subjects regarding 
age, sex, cognitive status, nutritional status, and risk factors. 
The cognitive domains that are related to body weight or nu-
tritional state have therefore remained unclear. In this study 
we demonstrated that PD patients with higher-than-normal 
BMI showed significantly reduced declines in language and 
memory functions, which are generally acknowledged to be 
the domains of cognitive dysfunction in patients with AD.25 
Fig. 2. Repeated-measures graphs for comparison of cognitive function among patients with PD grouped according to body mass index. *Signifi-
cant group×time interaction. †Significant difference between under-/normal-weight and overweight groups. ‡Significant difference between un-
der-/normal-weight and obese groups. Colored dot lines indicate a significant difference between the neuropsychological tests in the respective 
groups. CDR-SOB: Clinical Dementia Rating Sum of Boxes, MMSE: Mini Mental State Examination, PD: Parkinson’s disease.
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Additionally, overweight and obese patients with PD were 
less likely to progress to PDD. 
Amyloid-beta seems to be related to cognitive decline or 
aggregated cortical alpha-synuclein burden in patients with 
PD.30,31 Moreover, the patterns of brain atrophy in AD have 
been known to predict cognitive decline in PD.32 An autop-
sy study linked AD neuropathological changes with low and 
declining BMI.33 The presence and burden of biomarkers 
such as cerebrospinal fluid and PET imaging of cerebral am-
yloid and tau have been associated with lower BMI in indi-
viduals with normal cognition and MCI.34 In PD, the amyloid 
burden is more closely associated with cognitive function in 
PDD than it is in nondementia PD.35,36 All of the BMI groups 
in our study exhibited comparable cognitive profiles as well 
as MTA grades at baseline, and showed different cognitive 
declines during the follow-up. Together our findings suggest 
that PD patients with a higher BMI at the diagnosis are less 
susceptible to AD or a neuropathological burden compared 
to those with a low-to-normal BMI, resulting in slower cog-
nitive decline and a lower rate of conversion to dementia. 
A particularly intriguing finding was the significant deteri-
oration in visuospatial and frontal executive functions among 
the cognitive domains measured in the overweight and obese 
groups. This suggests that the cognitive decline in these do-
mains occurred independently of the BMI at the diagnosis 
and reflects a characteristic cognitive decline in PD. Previous 
longitudinal studies identified that memory and frontal ex-
ecutive functions consistently deteriorated,37 while visuospa-
tial function deteriorated significantly in only some studies.38 
Considering our findings together, any prominent deterio-
ration in memory function may differ depending on the ef-
fects of BMI or concomitant AD pathology. Since impairments 
in frontal executive and visuospatial functions are demonstra-
ble in Lewy-body disease and distinguishable features from 
AD,39 we can also speculate that BMI does not affect the cog-
nitive domains specific to PD, but rather the domains related 
to AD. Further research is needed into the association be-
tween BMI and pathological markers in PD, including am-
yloid or alpha-synuclein.
The exact pathomechanism underlying the effect of BMI 
on cognition in PD is still unknown. It is also unclear whether 
altered cognition directly leads to changes in BMI, or whether 
variations in BMI accelerate or decelerate the rate of cogni-
tive decline. Obesity can exert detrimental effects on vascular 
pathology, neuroinflammation, oxidative stress, and neuro-
endocrine regulation, and can negatively impact the cogni-
tive performance.40 A higher BMI has been reported to be as-
sociated with brain atrophy in widespread cortical regions.41 
Meanwhile, protective effects of BMI on cognition can be ex-
plained by substances such as insulin-like growth factor-1 and 
leptin, whose levels are higher in patients with a higher BMI 
and are associated with good cognitive function.42,43 Higher 
BMI has also been suggested to be a modulator of function-
al connectivity of the default mode network, thus conferring 
protective effects on cognition.44 This suggests that the BMI 
at a diagnosis of PD can affect the subsequent cognitive de-
cline, rather than being a co-occurring phenomenon or a re-
sult of cognitive dysfunction.
This study was subject to several limitations. First, we an-
alyzed a relatively small sample, which limits the generaliz-
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Fig. 3. Kaplan-Meier curves showing the cumulative probability of not developing dementia according to the duration of PD. A: The probability of 
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ability of the results. However, we applied strict inclusion and 
exclusion criteria, and closely followed the cognitive function 
of the included patients with PD for longer than 6 years. Sec-
ond, underweight patients with PD were pooled with those 
of normal weight due to the smallness of the sample, and so 
we could not evaluate the potential influence of being un-
derweight at baseline on cognitive decline. Third, we did not 
measure BMI when performing the follow-up NPs, and so 
we could not evaluate the relationship between BMI changes 
and cognitive deterioration. Regular longitudinal follow-ups 
of the BMI and cognition of PD patients are necessary to 
draw definitive conclusions about the association between 
BMI and cognition in PD. Fourth, a substantial number of 
patients was excluded during the longitudinal follow-up, 
which might have biased the results. Because several factors 
could affect cognition, applying strict exclusion criteria was 
important to investigating the independent relationship be-
tween BMI and cognitive decline. It can be argued that the 
18 patients who were followed up for shorter than 6 year 
would have been free of dementia at the final follow-up. Ac-
tually, 14 patients did not participate in the first follow-up 
NP, and so we could not evaluate their changes in cognitive 
function. Only one of four patients who underwent the first 3- 
year follow-up NP had converted to dementia, and that patient 
was in the under-/normal-weight group, which was found to 
be the most-vulnerable group for dementia conversion. How-
ever, it is unlikely that these features would have affected 
the overall results of this study. Finally, we did not evaluate 
the socioeconomic status of the study participants, which 
could be associated with BMI45 and cognitive status.46 How 
socioeconomic status is defined has varied among previous 
studies, and socioeconomic status is a comprehensive con-
cept that encompasses income, educational level, and occu-
pation.47 In contrast, we only investigated the years of edu-
cation at the time of cohort enrollment, which might be a 
reasonable and stable measure of socioeconomic status.48 The 
years of education did not differ among the groups in our 
study (p=0.441), and we included education as a covariate in 
all of the linear mixed models and survival analyses. How-
ever, future studies should evaluate the economic, educa-
tional, and occupational components of the socioeconomic 
status together.
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